ArticleNeuro-oncology advances
The MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromas.
Sadhana Jackson et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
22 papers cite it
pooled itcites it